Climb Bio, Inc.
NASDAQClimb Bio enters the week with the most notable analyst activity it has seen since its rebranding, as a fresh initiation from Guggenheim sets a price target that stands well above the rest of the Street. The analyst story here is the standout. Guggenheim initiated coverage on June 8 with a Buy rating and a $35 target — more than three times the current price of $11.44. That is a…
Snapshot as of 14 Jun 2026
Climb Bio enters the week with the most notable analyst activity it has seen since its rebranding, as a fresh initiation from Guggenheim sets a price target that stands well above the rest of the Street. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CLYM — free to start on ORTEX.
Sign up for free →Open CLYM on ORTEX